Australia markets closed
  • ALL ORDS

    7,552.10
    -40.60 (-0.53%)
     
  • AUD/USD

    0.7574
    +0.0021 (+0.28%)
     
  • ASX 200

    7,298.50
    -43.70 (-0.60%)
     
  • OIL

    73.37
    +0.52 (+0.71%)
     
  • GOLD

    1,783.50
    +6.10 (+0.34%)
     
  • BTC-AUD

    44,930.54
    +2,909.11 (+6.92%)
     
  • CMC Crypto 200

    813.96
    +19.63 (+2.47%)
     

CD40 Ligand Drugs Development Market Report 2021: T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG - ResearchAndMarkets.com

·3-min read

The "CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021 provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics.

The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development and features dormant and discontinued projects.

The report analyses the pipeline products across relevant therapy areas under development targeting CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG).

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the Global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG).

  • The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.

  • The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects.

  • The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

  • The report summarizes all the dormant and discontinued pipeline projects.

  • The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics.

Key Topics Covered:

  • Introduction

  • Report Coverage

  • Target - Overview

  • Target - Therapeutics Development

  • Products under Development by Stage of Development

  • Products under Development by Therapy Area

  • Products under Development by Indication

  • Products under Development by Companies

  • Products under Development by Universities/Institutes

  • Target - Therapeutics Assessment

  • Assessment by Mechanism of Action

  • Assessment by Route of Administration

  • Assessment by Molecule Type

  • Target - Companies Involved in Therapeutics Development

  • Target - Drug Profiles

  • Target - Dormant Products

  • Target - Discontinued Products

  • Target - Product Development Milestones

  • Featured News & Press Releases

  • Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ja8bys

View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005494/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting